Oncology

The first patient dosed with IOV-4001 has completed the safety observation period.

The chief medical officer of Triumvira Immunologics discussed the company’s future plans.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ORR was 80% in the first cohort of phase 1b at the recommended phase 2 dose.

A retrospective study measured correlations of ICANS and NfL in patients with a history of diffuse large B-cell lymphoma.

ALLO-501A received RMAT designation from the FDA in June 2022.

Lyell will soon initiate a phase 1 trial of LYL845 with initial data expected in 2024.

Review top news and interview highlights from the week ending October 7, 2022.

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.

The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.

The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.

Among the 11 patients evaluated for efficacy, 9 patients (81.8%) had objective responses at 28 days.

Disease-free survival was 56% in 105 participants over 3 years.

Review top news and interview highlights from the week ending September 30, 2022.

Of the 17 patients treated, 12 patients achieved a response, including 6 who achieved a complete response.

Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.

Verismo plans to initiate a phase 1, first-in-human trial of SynKIR-110 in the first quarter of 2023.

CTX-130 is being investigated in phase 1 studies for relapsed/refractory T or B-cell malignancies and renal cell carcinoma.

The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.

Hong Ma, senior vice president, clinical development, cancer immunotherapy, CARSgen, discussed data from a phase 1 trial of CT041.